Biohaven presents clinical safety and efficacy data for BHV-1510, a next-generation Trop2 ADC in combination with cemiplimab at the 2025 ESMO Immuno-Oncology Congress

CAR-T Digest - August 2020

Weekly Digest - December 2025

11 December 2025: Biohaven presents clinical safety and efficacy data for BHV-1510, a next-generation Trop2 ADC in combination with cemiplimab at the 2025 ESMO Immuno-Oncology Congress

Biohaven reported new clinical data for its next-generation Trop-2 targeting ADC, BHV-1510, presented at ESMO IO 2025, highlighting strong activity when combined with the anti-PD-1 agent cemiplimab
At the 2.5 mg/kg Q3W dose, the ADC-PD-1 combination delivered a 72.7% confirmed ORR, including robust responses across NSCLC, endometrial, urothelial cancers and a complete response in endometrial cancer
Across all dose levels, the regimen showed a 52.2% confirmed ORR with most patients achieving early tumor shrinkage and remaining on therapy beyond six months, indicating encouraging durability
Participants were heavily pretreated, most had prior PD-(L)1 exposure, yet the ADC combination maintained a favorable safety profile with manageable class-expected stomatitis and low rates of neutropenia, diarrhea and alopecia
With no treatment-related discontinuations, no interstitial lung disease, and stable pharmacokinetics characterized by minimal free payload in circulation, BHV-1510 is emerging as a differentiated Trop-2 ADC showing promising efficacy-tolerability balance across multiple tumor types